Pharmaceuticals

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

A new UK facility, backed by government funds, will be the only one of its kind, aiming to accelerate drug development and boost domestic life sciences.

A new patented drug, budiodarone, aims to treat atrial fibrillation in heart failure patients, a group with few safe options. Is this the future of care?

As a deadly superbug spreads, BioVersys's BV100 enters late-stage trials, backed by promising data and a novel scientific approach to combat resistance.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

Finance and governance powerhouse Suzanne Nora Johnson joins Wellcome Leap's board, a strategic move to supercharge its mission to solve health crises.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

As AI reshapes how patients get health info, new services aim to protect brands from inaccuracy, compliance risks, and reputational damage.

A new 'scar-less' protein purification technology promises to slash development timelines for complex biologics, accelerating the path to new medicines.

A novel sputum test could end the trial-and-error approach for millions with chronic respiratory disease, promising a new era of personalized medicine.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

Former Novo Nordisk CSO Marcus Schindler joins Cradle, validating AI's role in accelerating drug discovery and reshaping traditional pharmaceutical R&D.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.